News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,108 Results
Type
Article (41600)
Company Profile (463)
Press Release (659045)
Section
Business (208397)
Career Advice (2004)
Deals (35942)
Drug Delivery (92)
Drug Development (83301)
Employer Resources (169)
FDA (16325)
Job Trends (15045)
News (352086)
Policy (32979)
Tag
Academia (2619)
Alliances (50608)
Alzheimer's disease (1273)
Approvals (16250)
Artificial intelligence (139)
Bankruptcy (361)
Best Places to Work (11733)
Biotechnology (349)
Breast cancer (124)
Cancer (1115)
Cardiovascular disease (102)
Career advice (1673)
Cell therapy (248)
Clinical research (66000)
Collaboration (408)
Compensation (199)
COVID-19 (2590)
C-suite (100)
Data (1138)
Diabetes (156)
Diagnostics (6197)
Earnings (86044)
Employer resources (147)
Events (112927)
Executive appointments (316)
FDA (16871)
Funding (366)
Gene therapy (193)
GLP-1 (611)
Government (4409)
Healthcare (18995)
Infectious disease (2675)
Inflammatory bowel disease (113)
Interviews (308)
IPO (16573)
Job creations (3694)
Job search strategy (1429)
Layoffs (439)
Legal (7928)
Lung cancer (174)
Manufacturing (181)
Medical device (13322)
Medtech (13327)
Mergers & acquisitions (19433)
Metabolic disorders (426)
Neuroscience (1564)
NextGen Class of 2024 (6733)
Non-profit (4532)
Northern California (1496)
Obesity (245)
Opinion (198)
Patents (103)
People (57629)
Phase I (20682)
Phase II (29138)
Phase III (21546)
Pipeline (459)
Postmarket research (2590)
Preclinical (8882)
Radiopharmaceuticals (252)
Rare diseases (234)
Real estate (5998)
Regulatory (21956)
Research institute (2403)
Resumes & cover letters (351)
Southern California (1324)
Startups (3747)
United States (13873)
Vaccines (565)
Weight loss (183)
Date
Today (132)
Last 7 days (816)
Last 30 days (3886)
Last 365 days (36710)
2024 (33681)
2023 (41013)
2022 (52276)
2021 (56765)
2020 (54924)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (200)
Asia (38512)
Australia (6402)
California (3418)
Canada (1293)
China (252)
Colorado (148)
Connecticut (162)
Europe (83995)
Florida (462)
Georgia (116)
Illinois (354)
Indiana (199)
Kansas (99)
Maryland (590)
Massachusetts (2726)
Michigan (159)
Minnesota (278)
New Jersey (970)
New York (973)
North Carolina (759)
Northern California (1496)
Ohio (141)
Pennsylvania (852)
South America (1105)
Southern California (1324)
Texas (476)
Utah (92)
Washington State (374)
701,108 Results for "corcept therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)
Corcept Therapeutics Incorporated today announced that the results from GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome).
June 3, 2024
·
3 min read
Drug Development
Corcept Completes Enrollment in Phase 4 CATALYST Trial
Corcept Therapeutics Incorporated today announced completion of enrollment in CATALYST, a Phase 4 trial examining the prevalence of hypercortisolism.
April 29, 2024
·
3 min read
Business
Corcept Therapeutics to Announce First Quarter 2024 Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics Incorporated announced it will report first quarter financial results and provide a corporate update on May 1, 2024.
April 24, 2024
·
1 min read
Business
Corcept Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended March 31, 2024.
May 1, 2024
·
10 min read
Business
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 23, 2024
·
1 min read
Biotech Bay
Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that results from the prevalence phase of its CATALYST study of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 diabetes were presented at the American Diabetes Association’s 84th Scientific Sessions.
June 24, 2024
·
5 min read
Business
Corcept Appoints Roberto Vieira as President, Oncology
Corcept Therapeutics Incorporated today announced the appointment of Roberto Vieira as President, Oncology. He will report to Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer, and join the company’s Executive Team.
January 29, 2024
·
3 min read
Drug Development
Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that GRACE, the Phase 3 trial of its proprietary selective cortisol modulator relacorilant in patients with hypercortisolism (Cushing’s syndrome), met its primary endpoint.
May 28, 2024
·
4 min read
Business
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
Corcept Therapeutics Incorporated reported its results for the quarter and year ended December 31, 2023.
February 15, 2024
·
10 min read
Drug Development
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
Corcept Therapeutics Incorporated today announced completion of enrollment in DAZALS, a randomized, double-blind, placebo-controlled Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS).
April 15, 2024
·
3 min read
1 of 70,111
Next
